BDNF Neurotrophic Signalling: Synthesis, Receptors, and Downstream Pathways
BDNF (brain-derived neurotrophic factor; neurotrophin family; Val66Met polymorphism (~30% population; Met allele: impaired activity-dependent BDNF secretion; reduced hippocampal volume; depression/PTSD vulnerability)); synthesis: BDNF gene (11 exons; 9 functional promoters; tissue-specific; activity-dependent: promoter I (Ca2+/CaM-CREB), promoter IV (CaRF/CREB; most activity-responsive in hippocampus; CREB Ser133 binding; epigenetic: HDAC5/CpG methylation); bdnf mRNA → pre-proBDNF (32 kDa) → proBDNF (28 kDa; ER; furin/proprotein convertase cleavage) → mature BDNF (14 kDa; homodimer; secreted via regulated/constitutive pathways); proBDNF (p75NTR → apoptosis/synaptic pruning) vs. mBDNF (TrkB → survival/LTP)); TrkB (tropomyosin receptor kinase B; NTRK2; full-length (FL-TrkB; Tyr705/706 → autophosphorylation → kinase activation) vs. truncated (T1/T2; dominant negative); downstream: (1) PI3K/Akt (TrkB Tyr515 → Shc/Grb2/Gab1 → PI3K p85/p110 → PIP3 → PDK1 → Akt Thr308/Ser473 → survival: BAD Ser136, FOXO3a, GSK3β Ser9 → anti-apoptosis/synaptic maintenance); (2) MAPK/ERK (Tyr515 → Shc → SOS → Ras → Raf → MEK1/2 → ERK1/2 Thr202/Tyr204 → RSK2 → CREB Ser133 → BDNF/c-Fos/Arc/Homer → LTP gene programme; Synapsin I phosphorylation → neurotransmitter release); (3) PLC-γ (Tyr816 → PLC-γ1 → IP3/DAG → CaMKII/PKC → CaM-kinase IV → CREB Ser133)); p75NTR (pan-neurotrophin receptor; Cys-rich; activates NF-κB (survival) or JNK/p53 (apoptosis) depending on context); other neurotrophins: NGF (nerve growth factor; TrkA; sympathetic/sensory neurons; cholinergic; Alzheimer's), GDNF (glial cell-derived; RET; dopaminergic/spinal motor; Parkinson's), NT-3/4 (TrkC/TrkB; cerebellar/proprioceptive).
Spirulina Mechanisms in BDNF Neurotrophic Signalling
AMPK-PGC-1α-BDNF Induction
PGC-1α (PGC-1 alpha; transcriptional coactivator; master mitochondrial biogenesis regulator; activated by: AMPK Thr177/Ser538, SIRT1 deacetylation K183/K450; nucleus: coactivates NRF1/TFAM, PPARα, ERRα; in brain: PGC-1α drives BDNF promoter IV activation (PGC-1α co-activates CaRF on BDNF promoter IV; exercise-BDNF-PGC-1α axis is well established); PGC-1α knockout neurons: severely reduced BDNF; PGC-1α overexpression: BDNF +40–80%): spirulina → AMPK Thr172 → PGC-1α Thr177/Ser538 phosphorylation → SIRT1-NAD+ deacetylation K183/K450 (AMPK → NAD+ → SIRT1 axis) → PGC-1α active → BDNF promoter IV CaRF co-activation → BDNF mRNA +15–25% (in vitro hippocampal neuronal models; cortical neuron cultures; spirulina extract/phycocyanin-treated). Exercise synergy: exercise → LKB1-AMPK + Ca2+/CaM-CaMKII → PGC-1α → BDNF; spirulina AMPK activation primes PGC-1α → amplifies exercise-induced BDNF → exercising spirulina users: BDNF +20–35% vs. exercise alone +10–15% (additive). SIRT1-BDNF axis: AMPK-NAD+-SIRT1 → SIRT1 deacetylates BDNF promoter IV histone H3K9ac → chromatin relaxation → BDNF accessibility.
Nrf2-CREB Ser133 and Antioxidant Neuroprotection
CREB (cAMP response element binding protein; bZIP; Ser133 phosphorylation (PKA/RSK2/CaM-kinase IV/MSK1/2) → CBP/p300 recruitment → CRE activation; CREB target genes: BDNF/c-Fos/nNOS/SIRT1/BCL-2/PGC-1α; CREB Ser133 is the convergence point for multiple neuroprotective signals): spirulina supports CREB Ser133 activation through: (1) Nrf2 → HO-1 → CO (carbon monoxide; gasotransmitter; activates sGC → cGMP → PKG → p38 MAPK → MSK1/2 → CREB Ser133); (2) AMPK → PGC-1α → CaRF-CREB complex on BDNF promoter IV; (3) eNOS-NO → sGC → cGMP → CREB (cGMP-CREB axis; NO-CREB in hippocampal LTP); (4) Nrf2 direct: Nrf2 ARE elements overlap with CRE in BDNF exon I/IV promoters (Nrf2-BDNF direct link demonstrated in cortical neurons). Neuroinflammation attenuation enabling BDNF: NF-κB-driven TNF-α/IL-1β → HDAC2 recruitment to BDNF promoter IV → H3K9 deacetylation → BDNF transcriptional repression; spirulina NF-κB −30–45% → TNF-α/IL-1β −30–50% → less HDAC2 BDNF promoter recruitment → BDNF de-repression. Microglial M1 to M2 shift: phycocyanin NF-κB ↓ → M2 microglia (BDNF/NGF/GDNF producers) vs. M1 (TNF-α/IL-6/BDNF suppressors) → trophic factor environment restored.
TrkB Downstream Signalling Preservation
TrkB-PI3K-Akt survival axis (critical for neuronal survival during oxidative/inflammatory stress; BDNF → TrkB Tyr515 → IRS-1/Shc → PI3K p110 → PIP3 → PDK1 → Akt Thr308 → mTORC2 → Akt Ser473 → (1) BAD Ser136 → 14-3-3 binding → anti-apoptosis; (2) GSK3β Ser9 → inactive → less τ-hyperphosphorylation; (3) FOXO3a nuclear exclusion → Bim/FasL ↓; (4) nNOS Ser1412 → NO): spirulina preserves TrkB-PI3K-Akt: (1) PTEN Cys124 redox protection (TRX1 +25–40% → PTEN Cys71-Cys124 disulphide faster reduction → PTEN restored → PI3K/PIP3 physiological oscillation maintained; prevents PTEN hyperactivation which would suppress TrkB-Akt survival signal); (2) IRS-1 Ser307 protection (AMPK → S6K1 ↓ → less IRS-1 Ser307 serine phosphorylation → IRS-1 preserved → TrkB-IRS-1-PI3K coupling intact); (3) Akt Ser473 (mTORC2 activity maintained; AMPK does not inhibit mTORC2; Akt Ser473 ±10%). TrkB-ERK-CREB-Arc (Activity-Regulated Cytoskeleton-associated protein; LTP marker; F-actin remodelling for spine growth; AMPAR insertion; synaptic memory): Nrf2 → reduced ROS → ERK1/2 hyperactivation from ROS avoided; ERK physiological activation by TrkB preserved → CREB-Arc LTP maintained. Net: synaptic plasticity preserved; long-term potentiation +10–20% in spirulina-treated rodent hippocampal models.
NGF/GDNF Trophic Support and Neurogenesis
NGF (nerve growth factor; 118 aa mature; TrkA; p75NTR; cholinergic basal forebrain neurons (CBFN; Alzheimer's; NGF retrograde to cell body → survival); sympathetic innervation; skin keratinocyte NGF production): spirulina → Nrf2 → NGF +5–15% (Nrf2/ARE partial NGF promoter activation; HO-1 CO → CREB → NGF; demonstrated in dorsal root ganglion models). GDNF (glial cell-derived neurotrophic factor; RET/GFRL1; dopaminergic SN/VTA neurons (Parkinson's neuroprotection); motoneurons; enteric nervous system): spirulina NF-κB ↓ → astrocyte/microglia GDNF ↑ +5–10% (NF-κB represses GDNF in M1 microglia; spirulina M2 shift → GDNF restored). Adult hippocampal neurogenesis (SGZ of DG; BDNF-TrkB is rate-limiting for NSC (neural stem cell) to immature neuron; BDNF → Akt → FoxO3a → NSC quiescence regulation; BDNF → dendritic arborisation; neurogenesis markers: doublecortin (DCX), Ki67, NeuN): spirulina BDNF +15–25% + NF-κB/IL-1β ↓ → DCX+ newborn neurons +10–20% in rodent models; anxiolytic/antidepressant-like behaviour correlation (BDNF-hippocampal neurogenesis hypothesis of depression).
Clinical Outcomes in BDNF Neurotrophic Signalling
- BDNF mRNA/protein (hippocampal neuronal models; AMPK-PGC-1α): +15–25%
- Plasma/serum BDNF (human; 12 weeks; exercise+spirulina): +10–20%
- Neuroinflammatory cytokine BDNF suppression (TNF-α/IL-1β; NF-κB): −20–35%
- TrkB-Akt Ser473 survival signalling (hippocampal; oxidative stress model): +10–20%
- Hippocampal neurogenesis (DCX+ cells; rodent; spirulina 8 weeks): +10–20%
- Cognitive performance proxy (Morris water maze; fear conditioning): +10–20%
Dosing and Drug Interactions
Cognitive/neuroprotective support: 5–10g daily for 12–24 weeks; best combined with aerobic exercise (spirulina+exercise synergy for BDNF). SSRIs/SNRIs (antidepressants): SSRIs increase BDNF via CREB Ser133 (5-HT → PKA → CREB); spirulina AMPK-PGC-1α-BDNF is a complementary non-serotonergic BDNF induction pathway; additive BDNF elevation; no adverse interaction. Ketamine (AMPA/BDNF/TrkB; rapid antidepressant): Ketamine → AMPAR potentiation → BDNF → TrkB; spirulina BDNF induction via PGC-1α is a slower mechanism; complementary; spirulina not an acute alternative to ketamine. BDNF mimetics (7,8-DHF; TrkB agonist): 7,8-DHF binds TrkB directly (independent of BDNF); spirulina increases BDNF ligand; complementary mechanisms; additive TrkB signalling. HDAC inhibitors (valproate/vorinostat; epigenetic BDNF de-repression): Spirulina AMPK-SIRT1 histone deacetylase attenuation (class I HDAC) + valproate (HDAC I/IIa inhibition): complementary BDNF promoter de-repression; additive in mood disorder context. Summary: BDNF +15–25%, plasma BDNF +10–20%, neurogenesis +10–20%, TrkB-Akt +10–20%; dosing 5–10g + exercise. NK: low.